Literature DB >> 15580556

Pallidal deep brain stimulation influences both reflexive and voluntary saccades in Huntington's disease.

Adrian P Fawcett1, Elena Moro, Anthony E Lang, Andres M Lozano, William D Hutchison.   

Abstract

Deep brain stimulation (DBS) of the globus pallidus internus (GPi) is being evaluated as a potential new therapy for patients with Huntington's disease (HD). In addition to skeletal movement disorders, HD patients have difficulty initiating voluntary saccades and have difficulty in suppressing rapid saccades toward newly appearing stimuli. We measured several saccade parameters in an HD patient who had marked improvement of clinical symptoms with bilateral GPi DBS to determine whether oculomotor performance improved in parallel with clinical scores. Oculomotor performance was assessed using three testing paradigms: pro-saccades, anti-saccades, and memory-guided saccades. The data from the HD patient was also compared to that of two healthy controls. Pallidal DBS decreased pro-saccade latency, total movement time, and the number of correctly executed trials, as well as increasing saccade gain. Memory-saccade performance was negatively affected with stimulation: saccade gain decreased, latency increased, and the patient's ability to suppress unwanted saccades decreased with stimulation. Our data demonstrate a task-specific improvement of oculomotor deficits in this HD patient with pallidal DBS, supporting a role of GPi in oculomotor control. (c) 2004 Movement Disorder Society.

Entities:  

Mesh:

Year:  2005        PMID: 15580556     DOI: 10.1002/mds.20356

Source DB:  PubMed          Journal:  Mov Disord        ISSN: 0885-3185            Impact factor:   10.338


  6 in total

Review 1.  The importance of integrating basic and clinical research toward the development of new therapies for Huntington disease.

Authors:  Ignacio Munoz-Sanjuan; Gillian P Bates
Journal:  J Clin Invest       Date:  2011-02-01       Impact factor: 14.808

2.  Activity of neurons in monkey globus pallidus during oculomotor behavior compared with that in substantia nigra pars reticulata.

Authors:  SooYoon Shin; Marc A Sommer
Journal:  J Neurophysiol       Date:  2010-01-27       Impact factor: 2.714

Review 3.  Therapeutic Update on Huntington's Disease: Symptomatic Treatments and Emerging Disease-Modifying Therapies.

Authors:  Deepa Dash; Tiago A Mestre
Journal:  Neurotherapeutics       Date:  2020-10       Impact factor: 7.620

4.  Pallidal Deep Brain Stimulation Improves Higher Control of the Oculomotor System in Parkinson's Disease.

Authors:  Chrystalina A Antoniades; Pedro Rebelo; Christopher Kennard; Tipu Z Aziz; Alexander L Green; James J FitzGerald
Journal:  J Neurosci       Date:  2015-09-23       Impact factor: 6.167

Review 5.  Deep Brain Stimulation in Huntington's Disease-Preliminary Evidence on Pathophysiology, Efficacy and Safety.

Authors:  Lars Wojtecki; Stefan Jun Groiss; Christian Johannes Hartmann; Saskia Elben; Sonja Omlor; Alfons Schnitzler; Jan Vesper
Journal:  Brain Sci       Date:  2016-08-30

6.  Post-mortem Findings in Huntington's Deep Brain Stimulation: A Moving Target Due to Atrophy.

Authors:  Vinata Vedam-Mai; Daniel Martinez-Ramirez; Justin D Hilliard; Samuel Carbunaru; Anthony T Yachnis; Joshua Bloom; Peyton Keeling; Lisa Awe; Kelly D Foote; Michael S Okun
Journal:  Tremor Other Hyperkinet Mov (N Y)       Date:  2016-04-27
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.